Comparison of PEEP in Acute Decompensated Heart Failure

NCT04853563 | Unknown

• 1 other identifier: AMC_2021_0433
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

Little is known about optimal level of positive end-expiratory pressure (PEEP) in patiens who recieved invasive mechanical ventilation for acute decompensated heart failure. We therefore sought to compare clinical outcome according to low versus high PEEP.

Conditions

Heart Decompensation; Mechanical Ventilation Pressure High

Outcome Measures

Primary Outcomes (1)

• Ventilator-free day at 28-day

  Starting at the day of randomization, and the days on non-invasive ventilation do not count. Successful extubation is defined as at least 24 hours wihtout reintubation independent of invasive assisted ventilation in survivor. Non-survivor within 28 days: ventilator-free day counted as 0, ventilator-free day among only survivor at 28-day will be counted for primary endpoint.

  up to 28-day

Study Arms (2)

High PEEP

EXPERIMENTAL

Immediate after initiation of invasive mechanical ventilation and randomization, the PEEP level is set to be at 8 centimetre of water with an inspired oxygen fraction (FiO2) between 0.21 and 0.6. Thereafter, the PEEP level is adjusted to 1 centimetre of water higher to a minimum PEEP level of 10 with every 30 minutes.

Other: PEEP

Low PEEP

ACTIVE COMPARATOR

Immediate after initiation of invasive mechanical ventilation and randomization, the PEEP level is set to be at 5 centimetre of water with an inspired oxygen fraction (FiO2) between 0.21 and 0.6. In this arm, the PEEP level is adjusted to 1 centimetre of water lower to a minimum PEEP level of 3 with every 30 minutes while maintaining a partial pressure of arterial blood oxygen above 65 millimeter of mercury or oxygen saturation \>92% with pulse oxymetry.

Other: PEEP

Interventions

PEEP OTHER

High PEEP targeted to 10 cmH2O to be maintained during the period of mechanical ventilation compared with low PEEP maintaining 3-5 cmH2O

High PEEP; Low PEEP

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject who was diagnosed with congestive heart failure and objective evidence of pulmonary congestion (pulmonary edema on simple chest radiography or positive B-line on lung ultrasonography AND elevated B-type natriuretic peptide or N-terminal pro-brain natriuretic peptide level) as a reason for invasive mechanical ventilation
• Age over 19 years old
• Subject who agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the clinical site.

You may not qualify if:

• Subject who are on mechanical circulatory support (ECMO, intra-aortic balloon pump, VAD) at the time of randomization
• Subject who has cardiac abnormality that requires emergent or urgent percutaneous or surgical valvular procedure
• Subject who are on vasoactive or inotropic agents at least moderate dose defined as vasoactive-inotropic score \>10
• Isolated preload-dependent cardiac dysfunction (isolated right ventricular failure, right ventricular infarction, constrictive pericarditis, cardiac tamponade, severe pulmonary hypertension without LV dysfunction)
• Predominant right ventricular failure defined as following; clinical evidence of right ventricular failure by attending physician's discretion including hepatojugular reflux, Kussmaul sign, cardiac liver cirrhosis, hepato/splenomegaly, acites, thronmbocytopenia, etc.
• Subject who are not on mechanical ventilation before open heart surgery
• Subject who received unwitness cardiopulmonary rescucitation (CPR) or witness CPR lasting more than 30 minutes
• Subject who was already diagnosed or is suspected to have hypertophic cardiomyopathy with significant left ventricular outflow tract (LVOT) obstruction
• Subject with intracranial hemorrahge or ischemic stroke at the time of randomization
• Subject with irreversible neurologic damage or irreversible hepatic failure
• Invasive mechanical ventilation lasting more than 24 hours preceding endotracheal intubation
• Subject with underlying chronic obstructive pulmonary disease (GOLD classification III or IV) or restrictive pulmonary disease (e.g. interstitial lung disease)
• Subject with impaired consciousness that can not perform self coughing and need suction to maintain adequate airway patency
• Pregnant and/or lactating women
• Subject with life expectancy less than a year

Sponsors & Collaborators

• Asan Medical Center: lead

Study Sites (1)

Asan Medical Center

Seoul, 05505, South Korea

RECRUITING

Related Publications (1)

• Hyun J, Kim IC, Kim AR, Lee HJ, Lee SE, Yun SC, Kim MS. Comparison of High Versus Low Positive End-Expiratory Pressure in Mechanically Ventilated Patients With Acute Heart Failure: Rationale and Design of the HELP-AHF Trial. Int J Heart Fail. 2025 Apr 23;7(2):79-84. doi: 10.36628/ijhf.2025.0014. eCollection 2025 Apr.

  PMID: 40519712 DERIVED

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases

Central Study Contacts

Minseok Kim

CONTACT

(82-2)-3010-3948; msk@amc.seoul.kr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: professor of medicine

Study Record Dates

• First Submitted: April 20, 2021
• First Posted: April 21, 2021
• Study Start: April 20, 2021
• Primary Completion: July 30, 2023
• Study Completion: April 30, 2024
• Last Updated: February 23, 2022

Record last verified: 2022-02

Locations

KR (1)